Medigen Biotechnology (ROCO:3176) Ending Cash Position: NT$944 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:3176 Medigen Biotechnology Corp ROCO:3176
58 GF Score
Price NT$38.05
GF Value NT$32.97
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Medigen Biotechnology Ending Cash Position?

Medigen Biotechnology ROCO:3176 +4.25% 58 Ending Cash Position is NT$944 Mil as of Jun. 2026. GuruFocus rates ROCO:3176 with a GF Score™ of 58/100 and a GF Value™ of NT$32.97 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Medigen Biotechnology's Ending Cash Position for the quarter that ended in Jun. 2026 was NT$944 Mil.

Medigen Biotechnology's quarterly Ending Cash Position declined from Dec. 2025 (NT$1,324 Mil) to Mar. 2026 (NT$1,065 Mil) and declined from Mar. 2026 (NT$1,065 Mil) to Jun. 2026 (NT$944 Mil).

Medigen Biotechnology's annual Ending Cash Position declined from Dec. 2023 (NT$2,223 Mil) to Dec. 2024 (NT$1,388 Mil) and declined from Dec. 2024 (NT$1,388 Mil) to Dec. 2025 (NT$1,324 Mil).

Medigen Biotechnology Ending Cash Position Related Terms

Medigen Biotechnology Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Medigen Biotechnology's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Biotechnology Ending Cash Position Chart

Medigen Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,144.58 2,040.63 2,222.93 1,387.71 1,323.60

Medigen Biotechnology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 869.74 891.78 1,323.60 1,065.26 943.90
ROCO:3176
58GF Score
Medigen Biotechnology Corp ROCO:3176
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigen Biotechnology Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Medigen Biotechnology's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1387.713+-64.115
=1,324

Medigen Biotechnology's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1065.262+-121.361
=944

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of NT$944 Mil mean?
Medigen Biotechnology (ROCO:3176) has a Ending Cash Position of NT$944 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Medigen Biotechnology and its competitors.
Is Medigen Biotechnology's Ending Cash Position too high?
Medigen Biotechnology's current Ending Cash Position is NT$944 Mil. Overall, Medigen Biotechnology has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's Ending Cash Position compare to VRTX and REGN?
Medigen Biotechnology's Ending Cash Position of NT$944 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Medigen Biotechnology and its competitors. Medigen Biotechnology's current Ending Cash Position is NT$944 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$32.97, compared to a current price of NT$38.05 — trading 15.4% above its estimated fair value. The current Ending Cash Position is NT$944 Mil. Medigen Biotechnology's overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current Ending Cash Position is NT$944 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?

Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be overvalued. The current stock price of NT$38.05 is trading 15.4% above its estimated GF Value™ of NT$32.97. GuruFocus considers Medigen Biotechnology to be Modestly Overvalued.

Key valuation signals for ROCO:3176:

  • Ending Cash Position: NT$944 Mil
  • GF Value™: NT$32.97 vs. price of NT$38.05 (15.4% above fair value)
  • GF Score™: 58/100 with 7 warning signs

No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medigen Biotechnology Business Description

Address Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
58GF Score

Get the complete analysis for ROCO:3176

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$38.05
Price
NT$32.97
GF Value